Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi
{"title":"利拉鲁肽致肝损伤一例极为罕见。","authors":"Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi","doi":"10.1155/2021/6306149","DOIUrl":null,"url":null,"abstract":"<p><p>Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.</p>","PeriodicalId":45645,"journal":{"name":"Case Reports in Gastrointestinal Medicine","volume":"2021 ","pages":"6306149"},"PeriodicalIF":0.6000,"publicationDate":"2021-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405313/pdf/","citationCount":"2","resultStr":"{\"title\":\"An Exceedingly Rare Case of Liraglutide-Induced Liver Injury.\",\"authors\":\"Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi\",\"doi\":\"10.1155/2021/6306149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.</p>\",\"PeriodicalId\":45645,\"journal\":{\"name\":\"Case Reports in Gastrointestinal Medicine\",\"volume\":\"2021 \",\"pages\":\"6306149\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2021-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405313/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Gastrointestinal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/6306149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastrointestinal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/6306149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
An Exceedingly Rare Case of Liraglutide-Induced Liver Injury.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
